Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct-Dec;35(4):299-304.
doi: 10.4103/ijnm.IJNM_130_20. Epub 2020 Oct 21.

Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer

Swayamjeet Satapathy  1 , Bhagwant Rai Mittal  1 , Ashwani Sood  1 , Chandan Krushna Das  2 , Shrawan Kumar Singh  3 , Ravimohan Suryanarayan Mavuduru  3 , Girdhar Singh Bora  3
Affiliations

Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer

Swayamjeet Satapathy et al. Indian J Nucl Med. 2020 Oct-Dec.

Abstract

Aims: Actinium-225 (225Ac) labeled prostate-specific membrane antigen (PSMA)-617 is a novel treatment modality in the management of metastatic castration-resistant prostate cancer (mCRPC). The present study was conducted to assess the impact of 225Ac-PSMA-617 therapy on the quality-of-life of patients with heavily pretreated mCRPC using the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Prostate Symptom Index-17 (NCCN-FACT-FPSI-17) questionnaire.

Materials and methods: This was a retrospective single-center study where data of consecutive heavily pretreated mCRPC patients treated with 225Ac-PSMA-617 from January 2019 to February 2020, was collected and analyzed for the biochemical response, quality-of-life outcomes and treatment-related toxicity.

Results: Eleven heavily pretreated mCRPC patients received a median cumulative dose of 8.3 MBq (interquartile range [IQR] 5.6-20.4 MBq) 225Ac-PSMA-617 over 1-4 cycles. 5/11 patients (46%) showed a ≥50% decline in Prostate Specific Antigen (PSA), while stable values and PSA progression were observed in 3/11 (27%) patients each. Pre- and post-therapy NCCN-FACT-FPSI-17 questionnaires revealed statistically significant improvement in the total FPSI score (P = 0.003) as well as the disease-related symptoms-physical (P = 0.004) and disease-related symptoms-emotional (P = 0.046) subscores. Among the physical symptoms, significant improvement was noted with respect to pain, difficulty in urination, bone pain, fatigue, and restriction in physical activity. No significant change was noted in the treatment side-effects subscore. Of the treatment-related adverse effects, Grade 3 dryness of the mouth, anemia, and nephrotoxicity was observed in 1/11 patients (9%) each and Grade 3 thrombocytopenia in 2/11 patients (18%).

Conclusion: Health-related quality-of-life of the mCRPC patients improved significantly with 225Ac-PSMA-617 despite extensive pretreatment and advanced nature of the disease.

Keywords: Actinium-225-prostate-specific membrane antigen-617; castration-resistant prostate cancer; prostate-specific membrane antigen; quality-of-life.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Waterfall plot showing PSA response at 6 weeks following the last cycle of 225Ac-PSMA-617 therapy (n = 11)
Figure 2
Figure 2
Line diagram showing change in total FPSI-17 scores from baseline to post 225Ac-PSMA-617 therapy for the individual patients (n = 11)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Klaff R, Rosell J, Varenhorst E, Sandblom G. The long-term disease-specific mortality of low-risk localized prostate cancer: A prospective population-based register study over two decades. Urology. 2016;91:77–82. - PubMed
    1. Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer – A population-based analysis of 2 national cohorts. Cancer. 2018;124:2931–8. - PubMed
    1. Mottet N, Cornford P, van den Bergh RC, Briers E, De Santis M, Fanti S, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer EAU Guidelines Office. 2019
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed